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SUMMARY
A 62-year-old woman was referred to our pulmonology
team with exertional dyspnoea and chest tightness of
2 months duration. Her medical history included cervical
cancer and thyroid nodules. Imaging studies showed
collapse of left upper lobe. Fiberoptic bronchoscopy
unveiled an endoluminal lesion and bronchial biopsy
displayed features of melanoma. She denied a history of
melanoma or excision of lesions of skin, mucous
membranes or the eye. A thorough evaluation including
combined positron emission tomography with CT scan
excluded other possible sites of primary melanoma, but
there was a metastasis in a thoracic vertebra. Palliative
radiotherapy of the spine was performed. Chemotherapy
initiation with dacarbazine was postponed by the
appearance of a malignant pleural effusion, conﬁrmed
by pleural ﬂuid cytology. After four cycles chemotherapy
was discontinued due to disease progression. The
patient is still alive with a follow-up of 12 months,
currently on best supportive care.
BACKGROUND
Worldwide, approximately 160 000 new cases of
melanoma are diagnosed each year.1 It is known
that malignant melanoma occurs most frequently
on sunlight exposed areas, but it can also arise
from other organs and tissues.2 Among all, primary
pulmonary melanoma (PPM) is the rarest type of
visceral melanoma3 accounting for only 0.01% of
primary lung tumours.2 On the other hand, pul-
monary metastases are the most common presenta-
tion of advanced melanoma.4 Therefore, to assure
the diagnosis of PPM, an extrapulmonary origin
must be ruled out by a thorough evaluation.2 In
conﬁrmed cases, treatment of choice is surgical
resection with an oncologically adequate margin
and lymph node involvement at time of operation
does not seems to impair long-term survival.5
This case recalls that, although rare, melanoma
can be a primary lung tumour. An accurate diagno-
sis requires detailed investigation and fulﬁlment of
speciﬁc criteria and we believe a PET-CT scan may
assist this process.
CASE PRESENTATION
A 62-year-old Caucasian female was referred to our
pulmonology team with progressive exertional dys-
pnoea and persistent chest tightness with 2 months
of duration. Her medical history included a cervical
cancer 15 years ago, which was treated with total
hysterectomy and bilateral salpingo-oophorectomy.
She also reported having newly diagnosed thyroid
nodules still being evaluated by her family phys-
ician. She was a non-smoker. The physical examin-
ation was normal.
INVESTIGATIONS
A plain chest radiograph (PA view) showed a global
mediastinal shift to the left and a soft tissue opacity
in the left upper thorax with the shape of a semi-
circle, measuring about 35 mm of diameter. Its base
was located in the mediastinum causing a loss of
the normal radiographic contour of pulmonary
trunk and left auricular appendix—silhouette sign
(ﬁgure 1).
A thoracic CT scan was performed, conﬁrming
the mediastinal shift and revealing almost total col-
lapse of left upper lobe. Presence of an endolum-
inal lesion on the left upper lobe bronchus was
assumed. The remaining parenchyma was slightly
hyperinﬂated and no other alterations were appar-
ent (ﬁgure 2).
Fiberoptic bronchoscopy showed a polilobulated
endoluminal lesion occluding the entrance in the
left upper lobe bronchus, which was subjected to
bronchial biopsy. The tumour displayed histological
and immunohistochemical features compatible with
malignant melanoma (ﬁgures 3–8). It caused ulcer-
ation of the bronchial epithelium. A dark pigment
was observed in the cytoplasm of tumour cells,
which showed positive staining for S-100 and nega-
tive staining for keratin.
Figure 1 Chest radiograph (posteroanterior view)
showing a semicircular opacity in the left upper thorax
with the base located in the mediastinum (white arrows
show the lateral edge).
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Whole body PET-CT scan showed a hypermetabolic lung
lesion near the left hilum with 18 by 17 mm and 2 hypermeta-
bolic lesions suggestive of secondary nodal involvement (one in
the left hilum and another in the anterior mediastinum) and a
suspected lesion in the second thoracic vertebra (ﬁgure 9). Spine
CT scan and MRI conﬁrmed the suspected bone metastasis
(images not shown). A cranial CT scan showed no abnormalities
(images not shown).
When questioned, the patient denied a history of melanoma
or fulguration/excision of lesions of skin, mucous membranes or
the eye. We performed a systematic and detailed search of pos-
sible sites of primary melanoma, including an inspection of the
skin and mucous membranes, with assessment of scalp, palms
and plants, eye, nasopharyngeal and oral mucosa, perineum and
genitals.
DIFFERENTIAL DIAGNOSIS
The main differential diagnoses are PPM and pulmonary metas-
tases of melanoma. Diagnostic criteria and required evaluation
will be detailed during discussion.
TREATMENT
First, the patient underwent palliative radiotherapy of the spine.
She did not present BRAFV600E mutation and therefore was
proposed to chemotherapy with dacarbazine after discussion in
multidisciplinary meeting.
At the time scheduled to begin chemotherapy, the patient pre-
sented with symptoms of dyspnoea, with no other symptoms.
A left large pleural effusion was diagnosed. The patient was
admitted and underwent a diagnostic thoracentesis, which
revealed presence of malignant cells. The pleural cavity was evac-
uated, with symptom relief. Chemotherapy was then initiated.
Figure 2 Thoracic CT scan showing mediastinal shift to the left and
collapse of left upper lobe (white arrow) (A) lung window and (B)
mediastinal window.
Figure 3 Bronchial biopsy: H&E, ×100 magniﬁcation. Malignancy
with solid growth pattern underlying the mucosa.
Figure 4 Bronchial biopsy: H&E, ×400 magniﬁcation. Presence of
large cells with hyperchromatic and vesicular nuclei. Some cells have
dark brown pigment in the cytoplasm (white arrow).
Figure 5 Detail of the tumour, where one can see the migration of
malignant cells to the epithelium (white arrow). H&E, ×400
magniﬁcation.
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OUTCOME AND FOLLOW-UP
We have now 12 months of follow-up. Chemotherapy was dis-
continued after four cycles due to disease progression with new
vertebral metastases. Palliative radiotherapy was performed. The
patient is currently on the best supportive care.
DISCUSSION
The occurrence of a primary melanoma of the lung remains a
matter of controversy. Actually, the issue is ‘how can melanoma
develop as a primary lung neoplasm?’. For a melanoma to arise
from the lung, melanin-containing cells, which serve as a precur-
sor to the malignancy, must exist.6 These cells do not seem to
be present in normal tracheobronchial tree.6 However, some
investigators propose that pulmonary melanoma can arise from
a small number of melanoblasts present in the respiratory tract
due to the shared embryologic origin of trachea and oesopha-
gus,6 which is an organ with recognised existence of melano-
blasts.3 Despite this appealing assertion, during the investigation
of a suspected PPM one must always bear in mind that a malig-
nant melanoma of the skin might spontaneously regress despite
having metastasised,7 which poses a diagnostic challenge.
Distinguishing primary melanoma of the lung from metastatic
melanoma to the lung is not easy. In fact, lung metastasis may
occur in 12% of melanomas, being solitary in about 25%.8
Because of the aforementioned, histological and clinical
criteria for PPM were established.
Allen and Drash9 proposed histological criteria. These
included (1) junctional change with nesting of melanoma cells
just beneath the bronchial epithelium; (2) invasion of bronchial
epithelium by the malignant cells in an area without epithelial
ulceration and (3) an obvious melanoma beneath the above
described changes. However, the inability to demonstrate an
intraepithelial component or nevus associated with the invasive
component should not preclude the diagnosis of primary lung
melanoma.10 Another important aspect is the existence of ulcer-
ation of the bronchial epithelium. On one side, there are reports
of metastatic melanomas to the lung which exhibit intraepithe-
lial growth.11 On the other hand, in some cases of PPM an over-
growth of the invasive component may occur, with ulceration of
bronchial epithelium.10 Therefore, some authors consider that
the presence of an in situ component is not a reliable criterion
of primary pulmonary origin10 and that the presence of an
intraepithelial component should not be included in the diag-
nostic criteria of PPM.11
Allen and Drash9 also warned that melanomas can masquer-
ade as poorly differenciated carcinomas, ﬁbrosarcomas, liposar-
comas and other histological types of tumour such that the
pathologist must ‘think melanoma’ in order to diagnose
melanoma.
The clinical criteria proposed by Jensen and Egedorf12 are
now broadly accepted. The diagnosis requires four clinical cri-
teria: (1) a solitary lung mass or nodule; (2) typical histopath-
ology conﬁrmed by immunohistochemistry and/or electron
microscopy; (3) no prior history of melanoma or excision/ful-
guration of a cutaneous, mucous membrane or ocular lesion
unless the pathological examination explicitly ruled out a melan-
oma and (4) no demonstrable melanoma outside the chest at the
time of diagnosis.
Histopathological and clinical criteria should be pursued to
ensure the diagnosis of PPM. But although the diagnosis is still
based in old criteria that refer to features present at surgery, the
current widespread use of PET-CT warrants some comments
and probably justiﬁes a review of these criteria. PET with
18F-ﬂuorodeoxyglucose (18F-FDG) has already demonstrated its
utility in cancer, namely in lung carcinoma or lymphoma. Given
Figure 6 Bronchial biopsy: immunohistochemistry—vimentin
antibody staining, ×200 magniﬁcation. Diffuse and intense
immunoreactivity for neoplastic cells.
Figure 7 Bronchial biopsy: immunohistochemistry—S100 antibody
staining, ×200 magniﬁcation. Focal and moderately intense
immunoreactivity for neoplastic cells.
Figure 8 Bronchial biopsy: immunohistochemistry—melanin stain,
×200 magniﬁcation. Intense immunoreactivity for neoplastic cells.
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the rarity of the disease, there are no large studies to deﬁne the
exact role of a PET-CT in the investigation of PPM. However,
some authors already described this exam as part of the diagnos-
tic process. Praske et al10 and Neri et al13 reported cases of
PPM in which a PET-CT scan was performed to conﬁrm the
hypothesis, showing the absence of a tumour outside the
thorax. In their report of a case of PPM Ouarssani et al14 stated
that advent of PET scans will deﬁnitely change the diagnostic
attitude since the probability of PPM increases if there is a
single pulmonary uptake of 18F-FDG and histological diagnosis
of melanoma. In fact, given its higher frequency, most studies
about PET scan and melanoma are performed on cutaneous
tumours. Nevertheless, some ideas can probably be extrapolated
and applied to the PPM. Much like what happens with PPM,
the main concern in cutaneous malignant melanoma is to
exclude other sites of disease. But in this case the objective is
deciding the most appropriate treatment. It is recognised that
conventional imaging methods (radiography, ultrasonography,
CT and MRI) may overlook secondary locations, because they
are based solely on the existence of a morphological differ-
ence.15 Therein arises PET scan, as it also provides a functional
image. PET scan may be useful in distant staging16 such as soft
tissue, lymph nodes and viscera15 with high speciﬁcity and
intermediate-high sensitivity.17 Fusion image of PET-CT scan
allows a more precise diagnosis that isolated PET.15 Concerning
the role of PET-CT scan in the diagnosis of PPM we can prob-
ably assert the diagnosis with conﬁdence in a patient without a
history of extrapulmonary melanoma and with no suspected
lesions outside the thorax in a PET-CT.
Our research, conducted in MEDLINE with the interface
PubMed from 1947 to the present, in all languages, identiﬁed
more than 40 published cases of PPM. Yet it is known that
many do not meet the requested criteria, the main problem
being the lack of trustworthy exclusion of an extrapulmonary
origin. Reliable data about clinical behaviour, tumour markers,
diagnostic modalities and prognostic factors are limited because
of lack of large series.5
A review of English language literature published in 19996
found 19 cases which met the clinical criteria of Jensen and
Egedorf. From 13 patients in whom ﬁberoptic bronchoscopy
was performed, 8 had endobronchial disease. Among these,
only four had a black or pigmented lesion. The frequent endo-
bronchial location justiﬁes the common symptoms: cough, hae-
moptyses, postobstructive pneumonia, lobar collapse and
atelectasis.5 The same review reported that 6 of 15 patients
(40%) who underwent surgical resection of the tumour had
lymph node involvement documented at the time of surgery.
Two of these patients were free of disease at 3 and 11 years.
The success of radical resection, with median survival of
30 months, suggested that an aggressive surgical approach with
anatomic resection plus hilar and mediastinal lymphadenectomy
must be the rule in PPM. Other authors also showed that prog-
nosis for surgically resected patients is better than for non-
surgically treated patients.18 It is also proposed that adjuvant
chemotherapy may prevent recurrences or distant metastases.3
Treatment with dacarbazine and immunotherapy with
interleukin-2 or interferon are described.18
A detailed medical history, a complete physical examination
and ancillary studies make us believe that our patient had, at the
time of diagnosis, a PPM with secondary nodal and bone
involvement. She was excluded from surgical treatment because
of the existence of bone metastasis and as she is still alive we do
not have data on the autopsy. Between the end of palliative
bone radiotherapy and chemotherapy start it was also diagnosed
a malignant pleural effusion. In our case, PPM was successfully
diagnosed based on bronchial biopsy, although there are known
cases of misdiagnosis by such means that only come to be recti-
ﬁed after surgery.3
Learning points
▸ Although rare, primary melanoma of the lung should be
considered in the differential diagnosis of a primary
bronchial tumour.
▸ Histopathological and clinical criteria have been proposed
and should be applied to ensure the diagnosis of primary
melanoma of the lung. However, the widespread use of
modern examinations, such as PET-CT scan, may assist the
diagnosis process and probably justiﬁes a review of these
criteria.
▸ Melanomas can masquerade as other histologic types of
tumour such that the pathologist must ‘think melanoma’ in
order to diagnose melanoma.
▸ The success of radical resection suggests that an aggressive
surgical approach with anatomic resection plus hilar and
mediastinal lymphadenectomy must be the rule in PPM.
▸ Lymph node involvement at time of operation does not
seems to impair long-term survival.
Figure 9 Positron emission tomography-CT scan showing a hypermetabolic lung lesion near the left hilum and an adjacent hypermetabolic lesion
suggestive of secondary nodal involvement (white arrows).
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